
Drive Your Drug Discovery with an Enhanced Live-Cell Metabolic Assay Platform

New Agilent Seahorse XF Pro for pharma and biopharma



Detect rapid, real-time changes in cellular bioenergetics with a platform optimized for pharma

The analyzer that revolutionized measuring bioenergetics in live cells now features new pharma-oriented workflow solutions with advanced experimental design and analysis tools. Now, Agilent Seahorse XF data interpretation is even easier for characterizing *in vitro* disease models, identifying novel drug targets, validating target effect on cellular function, developing functional (mechanistic) screening assays, determining drug safety, and measuring parameters linked to antitumor potential of T cell therapies.

Newly updated end-to-end solution for performing, interpreting, and determining cell function

Agilent Seahorse Wave Pro software

Import assay conditions and plate map layouts, reduce data complexity with automated and interactive data quality analysis report



Agilent Seahorse XF Pro analyzer and controller software

Improved sensitivity and precision for OCR, improved usability and temperature performance, verified optimal OCR and PER measurement ranges, automation-ready

Agilent Seahorse Analytics

New data visualizations and customizable analysis templates facilitate decision making, compile and summarize result data from multiple XF assays



New Agilent Seahorse XF consumables

XF Pro M fluxpak and plates designed to limit edge effects for larger screens, 96-well hydrobooster for improved sensor calibration, XF Mito Tox Assay kit, XF T Cell Metabolic Profiling kit



- Verified instrument performance. Maintain consistent XF data from plate to plate with verified CV% and standard deviations for OCR/ECAR/PER rates.
- Wave Pro data quality view. Automatically flag erroneous data and more easily reject outliers.
- Optimized temperature control. Control edge effects when combined with the new Agilent Seahorse XF Pro M cell culture plate.
- Automation enabled. Software is designed to communicate with automation integration software.
- Analytical instrument qualification (AIQ) service. Ensure proper instrument performance through customer acceptance criteria and documentation.



Seahorse XF cellular analysis in preclinical therapeutic discovery

Whether your drug discovery strategy is small molecule, biologic, or cell therapy, Agilent Seahorse XF assays help you elucidate the role of energy metabolism in cellular processes.

Applications for Seahorse XF assays

Discovery research

- Disease biology
- Cell analysis
- Molecular
- OMICS

Target identification and validation

- Expression
- Cell-based disease model
- Animal model
- Pharmacological tools
- Functional analysis
- Mechanism of action
- In vitro/in vivo/ex vivo genetic manipulation

Small molecule and biologic

Lead discovery

- HTS
- Focused screen
- Physiological screen
- In vitro/in vivo/ex vivo secondary (mechanistic) assays

Cell therapy

Target selection

Product and bioprocess development

- Optimize gene, vector, transfection
- Characterize engineered cells
- Optimize growth, scaleup, media, freeze/thaw, process timing

Preclinical saftey and toxicity

- In vitro ADME
- PK/PD

Candidate selection

- In vitro safety tox
- Mitochondrial toxicity

Bioprocess validation

- Validate production process
- Determine critical quality attributes
- Release product

To learn more about advancing your live-cell metabolic analysis, contact your Agilent representative.

www.agilent.com/chem/discoverxf

For Research Use Only. Not for use in diagnostic procedures. RA44511.6029282407

This information is subject to change without notice.

- IND fill